Juniper Biologics
NEWS PROVIDED BYJuniper Biologics 24 Jun, 2024, 01:00 GMT SINGAPORE, June 24, 2024 /PRNewswire/ — Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences (Caris)’ solid tumour molecular profiling services in the Middle East and Africa (MEA). Caris is the leading next-generation AI TechBio company … Read more
Read More
NEWS PROVIDED BY Juniper Biologics Apr 21, 2024, 21:00 ET SINGAPORE, April 18, 2024 /PRNewswire/ — Juniper Biologics (“Juniper“), a global science-led pharmaceutical company dedicated to advancing treatments in specialised therapy areas, has been named “Pharmaceutical Company of the Year” by the Corporate LiveWire Global Awards for the year 2023-2024. The Corporate LiveWire Global Awards spotlight the outstanding achievements … Read more
Read More
SINGAPORE, 25 MARCH 2024 – Juniper Biologics (“Juniper”), Singapore-based science-led pharmaceutical company focused on researching, developing, and commercializing novel therapies, celebrates another milestone as it received the award for Best Novel Therapy R&D and Commercialization Company at the APAC Insider Singapore Business Awards 2024. The APAC Insider Singapore Business Awards serves to spotlight companies and … Read more
Read More
2024-01-08 09:00 SINGAPORE, Jan. 8, 2024 /PRNewswire/ — Juniper Biologics (“Juniper“), a global science-led pharmaceutical company headquartered in Singapore, proudly announces its latest achievement, winning the award for Molecular Science & Technology Acquisition of the Year at Acquisition International’s M&A Awards 2023. This recognition highlights Juniper’s unwavering commitment to advancing treatments in oncology-supportive care and its … Read more
Read More
https://www.prnewswire.co.uk/news-releases/juniper-therapeutics-acquires-exclusive-rights-for-sar-registration-for-anti-viral-covid-19-drug-from-ping-an-shionogi-hong-kong-for-singapore-302021003.html?tc=eml_cleartime
Read More
SINGAPORE, 23 OCTOBER 2023 – Juniper Biologics, a global science-led pharmaceutical company headquartered in Singapore, has been honored with the prestigious title of the “Most Innovative Oncology Pharmaceutical Company 2023” by the Global Health & Pharma (GHP) Healthcare and Pharmaceutical Awards. This recognition underscores Juniper Biologics’ commitment to advancing healthcare by delivering groundbreaking therapies in … Read more
Read More
SINGAPORE, JANUARY 12, 2023: Singapore-headquartered Juniper Biologics Pte Ltd, a science-led healthcare company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences® (Caris)’ molecular profiling services in South East Asia. Caris is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare. The company’s … Read more
Read More
We’re proud to announce that we’ve won Acquisition International Magazine’s M&A Award 2022 for Best Cell & Gene Therapy Acquisition 2022, in recognition of our licensing deal for TG-C LD ! This acquisition was our first step in ensuring patients suffering from osteoarthritis receive the treatment they need and have the quality of life they deserve. … Read more
Read More
Juniper Biologics’ investment will support the growth and innovation of Singapore’s pharmaceutical sector 15 Sept 2022, Singapore: Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, today announced the establishment of its Global Headquarters in Singapore, from where the Company will continue the expansion of its global operations. This announcement was supported by … Read more
Read More
Lugano, Switzerland, September 1, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and Juniper Biologics Pte Ltd, a science-led healthcare company focused on researching, developing and commercializing novel therapies, announced today the signing of an exclusive distribution license and … Read more
Read More